Under diagnosis and over diagnosis of prostate cancer

被引:60
作者
Graif, Theresa
Loeb, Stacy
Roehl, Kimberly A.
Gashti, Sara N.
Griffin, Christopher
Yu, Xiaoying
Catalona, William J.
机构
[1] Northwestern Feinberg Sch Med, Dept Urol, Chicago, IL USA
[2] Georgetown Univ, Sch Med, Dept Urol, Washington, DC USA
[3] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA
关键词
prostate; prostatic neoplasms; diagnosis; mass screening; prostate-specific antigen;
D O I
10.1016/j.juro.2007.03.017
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We quantified the rates of over and under diagnosis of prostate cancer in 2 large patient cohorts during the last 15 years. Materials and Methods: A total of 2,126 men with clinical stage T1c prostate cancer were treated with radical prostatectomy during 1 of the 3 periods 1989 to 1995, 1995 to 2001 and 2001 to 2005. The respective proportions of men with a tumor that met our criteria for over diagnosis (0.5 cm(3) or less, confined to the prostate with clear surgical margins and no Gleason pattern 4 or 5) and under diagnosis (nonorgan confined, pathological stage T3 or greater, or positive surgical margins) were examined. Results: The proportion of men with an over diagnosed tumor was 1.3% to 7.1%. The proportion with prostate cancer that was under diagnosed was 25% to 30%. An ancillary finding was that decreasing the prostate specific antigen threshold for biopsy from 4.0 to 2.5 ng/ml in the screened population resulted in a lower rate of under diagnosis from 30% to 26%, a higher rate of over diagnosis from 1.3% to 7.1% and an increase in the 5-year progression-free survival rate from 85% to 92%. Men who were 55 years or younger were significantly more likely to meet our criteria for over diagnosed cancer. Conclusions: Under diagnosis of prostate cancer continues to occur more frequently than over diagnosis. Lowering the prostate specific antigen threshold for recommending biopsy to 2.5 ng/ml resulted in a lower rate of under diagnosis and a higher progression-free survival rate.
引用
收藏
页码:88 / 92
页数:5
相关论文
共 19 条
[1]  
*AM CANC SOC, CANC FACTS FIG 2007
[2]  
[Anonymous], SEER STAT DAT MORT A
[3]   Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer [J].
Draisma, G ;
Boer, R ;
Otto, SJ ;
van der Cruijsen, IW ;
Damhuis, RAM ;
Schröder, FH ;
de Koning, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :868-878
[4]   MISCAN: estimating lead-time and over-detection by simulation [J].
Draisma, G ;
De Koning, HJ .
BJU INTERNATIONAL, 2003, 92 :106-111
[5]   PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER [J].
EPSTEIN, JI ;
WALSH, PC ;
CARMICHAEL, M ;
BRENDLER, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05) :368-374
[6]  
Etzioni R, 2002, J NATL CANCER I, V94, P981
[7]   An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series [J].
Han, M ;
Partin, AW ;
Chan, DY ;
Walsh, PC .
JOURNAL OF UROLOGY, 2004, 171 (01) :23-26
[8]   Viewpoint: Limiting prostate cancer screening [J].
Hoffman, RM .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (06) :438-440
[9]  
Humphrey PA, 1997, MODERN PATHOL, V10, P326
[10]   Prognostic impact of positive surgical margins in surgically treated prostate cancer:: Multi-institutional assessment of 5831 patients [J].
Karakiewicz, PI ;
Eastham, JA ;
Graefen, M ;
Cagiannos, I ;
Stricker, PD ;
Klein, E ;
Cangiano, T ;
Schröder, FH ;
Scardino, PT ;
Kattan, MW .
UROLOGY, 2005, 66 (06) :1245-1250